Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Oric Pharmaceuticals Q3 2026 Results: Net Loss of $48.1M, Loss Widens

For the nine months ended September 30, 2026, ORIC Pharmaceuticals reported a net loss of $125.3 million, an increase from the $99.0 million loss in the prior year period, primarily driven by higher research and development expenses. As of September 30, 2026, the company maintained a strong liquidity position with $345.4 million in cash, cash equivalents, and investments.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-48.1-32.6
EPS (diluted, $ a share)$-0.44$-0.33

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ORIC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Oric Pharmaceuticals, Inc.: key numbers

Share price
$7.52Close, Nov 16
Market cap
$782M
Shares outstanding
103.93MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Oric Pharmaceuticals, Inc.

All →
4:29 PM ET 8-K
Financial Results

Oric Pharmaceuticals Financial Results

ORIC Pharmaceuticals reported third quarter 2026 financial results and provided updates on its late-stage oncology portfolio, including the initiation of the Himalayas-1 Phase 3 trial for rinzimetostat in prostate cancer. The company ended the quarter with $345 million in cash and investments, which is expected to fund operations into the second half of 2028.

“Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC.”

Jacob M. Chacko, M.D., president and chief executive officer

“With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer.”

Jacob M. Chacko, M.D., president and chief executive officer
8:01 AM ET 8-K
Clinical Trial Data

Oric Pharmaceuticals Clinical Trial Data

ORIC Pharmaceuticals reported updated Phase 1b data for enozertinib (ORIC-114) in patients with EGFR-mutant non-small cell lung cancer, showing an 84% confirmed systemic objective response rate. The data, presented at the ESMO Congress 2026, also highlighted significant intracranial activity and plans to initiate a global Phase 3 registrational trial in the first half of 2027.

5:17 PM ET Form 4
Insider Selling

Oric Pharmaceuticals CFO Dominic Piscitelli Sells $189K of Stock

Dominic Piscitelli, CFO, sold 14,000 shares of Oric Pharmaceuticals, Inc. at $13.53 a share, worth $189K in total on Oct 20, 2026. Shares held after the trade: 69,828 (-16.7%).

Value
$189K
Shares
14,000
Price
$13.53
Role
CFO
Holding change
-16.7%
Trade date
Oct 20, 2026
5:51 PM ET Form 4
Insider Selling

Oric Pharmaceuticals Director Richard A. Heyman Sells $86.5K of Stock

Richard A. Heyman, Director, sold 6,700 shares of Oric Pharmaceuticals, Inc. at $12.91 a share, worth $86.5K in total on Oct 1, 2026. Shares held after the trade: 203,472 (-1.5%).

Value
$86.5K
Shares
6,700
Average price
$12.91
Role
Director
Holding change
-1.5%
Trade date
Oct 1, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.